KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Revenue (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Revenue for 18 consecutive years, with $246.1 million as the latest value for Q1 2026.

  • For Q1 2026, Revenue rose 86.98% year-over-year to $246.1 million; the TTM value through Mar 2026 reached $884.1 million, up 23.27%, while the annual FY2025 figure was $943.7 million, 33.83% up from the prior year.
  • Revenue hit $246.1 million in Q1 2026 for Ionis Pharmaceuticals, up from $203.3 million in the prior quarter.
  • Across five years, Revenue topped out at $324.5 million in Q4 2023 and bottomed at $119.5 million in Q1 2024.
  • Average Revenue over 5 years is $182.1 million, with a median of $156.7 million recorded in 2025.
  • Year-over-year, Revenue surged 153.15% in 2022 and then plummeted 30.18% in 2024.
  • Ionis Pharmaceuticals' Revenue stood at $151.9 million in 2022, then skyrocketed by 113.64% to $324.5 million in 2023, then tumbled by 30.18% to $226.6 million in 2024, then fell by 10.26% to $203.3 million in 2025, then rose by 21.03% to $246.1 million in 2026.
  • According to Business Quant data, Revenue over the past three periods came in at $246.1 million, $203.3 million, and $156.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.